Table 4 Pharmacokinetics of daunorubicin and cytarabine of the FAMYLY study compared to those of previous studies.
Study | N | Drug dosing | Inf. time | Cmax (mg/L) | AUC (ng.h) | Cl (L/h) | T1/2 (h) |
|---|---|---|---|---|---|---|---|
Daunorubicin | |||||||
4 | 1–1.5 mg/kg | 45 min | 475 ± NE | 600 ± NE | NE | NE | |
70 | 60 mg/m2 | 60 min | 200 ± 180 | 320 ± NE | 270 ± 226 | 22.4 ± 15.4 | |
12 | 50 mg/m2 | 15 min | 210 ± 185 | 517 ± 296 | 221 ± 107 | 7.9 ± 3.0 | |
21 | 45 mg/m2 | IV bolus | NE | 226 [31.6–570] | 590 [90–2770] | 1.5 [0.11–11.9] | |
24 | 50 mg/m2 | 60 min | 105 ± NE | NE | 129 ± 54 | NE | |
FAMYLY | 10 | 60 mg/m2 | 15 min | 92.2 ± 82.9 | 415 ± 276 | 359 ± 15 | 3.5 ± 1.0 |
Cytarabine | |||||||
200 mg/m2/d | 7d IVc | 73.0 [12–266] | NE | 135 ± 71 | NE | ||
FAMYLY | 200 mg/m2/d | 7d IVc | 44.1 ± 69.8 | 72.1 ± 101.4 | 1 628 ± 1 672 | 10.7 ± 6.8 | |
